Congress given chance to reduce threat for brand-name pharma from Hatch-Waxman and IPR challenges

Congress given chance to reduce threat for brand-name pharma from Hatch-Waxman and IPR challenges

US Senator Orrin Hatch has introduced a legislative amendment which would prevent generic drug companies from challenging brand-name drug patents using both the Hatch-Waxman and an inter partes review (IPR) routes. Instead, they would be forced to…

Unlock unlimited access to all IAM content